公开(公告)号：US11739065B2

公开(公告)日：2023-08-29

申请号：US17537250

申请日：2021-11-29

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D261/10 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  A61K31/42 ,  A61K31/44 ,  C07C13/04 ,  C07C25/13 ,  C07C39/28 ,  C07D205/02

CPC classification number: C07D261/10 ,  A61K31/42 ,  A61K31/44 ,  C07C13/04 ,  C07C25/13 ,  C07C39/28 ,  C07D205/02 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US10774054B2

公开(公告)日：2020-09-15

申请号：US16541073

申请日：2019-08-14

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D261/10 ,  C07D205/02 ,  C07C39/28 ,  C07C25/13 ,  C07C13/04 ,  A61K31/44 ,  A61K31/42 ,  C07D413/14 ,  C07D413/12 ,  C07D401/14

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US20190308962A1

公开(公告)日：2019-10-10

申请号：US16308915

申请日：2017-06-09

Applicant: GILEAD SCIENCES, INC.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D413/14 ,  C07D401/14 ,  C07D413/12

Abstract: The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US20200369632A1

公开(公告)日：2020-11-26

申请号：US16989335

申请日：2020-08-10

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D261/10 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  A61K31/42 ,  A61K31/44 ,  C07C13/04 ,  C07C25/13 ,  C07C39/28 ,  C07D205/02

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US20190315729A1

公开(公告)日：2019-10-17

申请号：US16409184

申请日：2019-05-10

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Julie Farand ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D413/14 ,  C07D401/14

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US10421730B2

公开(公告)日：2019-09-24

申请号：US15618666

申请日：2017-06-09

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D261/10 ,  C07D205/02 ,  C07C13/04 ,  C07C25/13 ,  C07C39/28 ,  A61K31/42 ,  A61K31/44 ,  C07D401/14 ,  C07D413/14 ,  C07D413/12

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US10329286B2

公开(公告)日：2019-06-25

申请号：US15619675

申请日：2017-06-12

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Julie Farand ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D413/14 ,  C07D401/14

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US20220204460A1

公开(公告)日：2022-06-30

申请号：US17537250

申请日：2021-11-29

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D261/10 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  A61K31/42 ,  A61K31/44 ,  C07C13/04 ,  C07C25/13 ,  C07C39/28 ,  C07D205/02

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US11247986B2

公开(公告)日：2022-02-15

申请号：US16409184

申请日：2019-05-10

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Julie Farand ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D401/14 ,  C07D413/14

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

公开(公告)号：US20200071282A1

公开(公告)日：2020-03-05

申请号：US16541073

申请日：2019-08-14

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Kevin S. Currie ,  Christian Gege ,  Jeffrey E. Kropf ,  Jianjun Xu

IPC: C07D261/10 ,  C07D205/02 ,  C07C39/28 ,  C07C25/13 ,  C07C13/04 ,  A61K31/44 ,  A61K31/42 ,  C07D413/14 ,  C07D413/12 ,  C07D401/14

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.